
Next generation cancer diagnostics — bridging healthcare IT and diagnostics.
Harae Dx is developing the world's first low-cost, portable, fully automated AI-based cancer detection system. The company's proprietary, patented technology platform is designed to detect cancer biomarkers with unprecedented speed and efficiency, delivering complete automated functional results in approximately 30 minutes without sending specimens to third-party laboratories. The system targets breast cancer detection and other cancer biomarkers, achieving 85% sensitivity and 91% specificity. Harae Dx is headquartered in Pleasanton, California.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account